DURHAM, N.C.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the opening of a new, $1 billion, 225,000-square-foot facility dedicated to ...

(KCTV) - Another major economic project is in the works for west Johnson County, Kansas. Merck Animal Health announced on Thursday morning that it plans to invest $895 million in the expansion of ...

KANSAS CITY, Mo. — Merck Animal Health announced Thursday plans to expand its operations in Johnson County, creating hundreds of new jobs. The biopharmaceutical company will invest $895 million ...

Drugmaker Merck said Tuesday it is investing $1 billion in a new Delaware plant to expand domestic production as it prepares to deal with President Trump’s tariffs. The new facility will produce ...

Thousands of jobs could be on the horizon for American workers as drug manufacturer Merck takes steps to move manufacturing into the U.S., particularly in the form of a $1 billion state-of-the-art ...

Merck & Co. will grow its U.S. manufacturing footprint with a $1 billion plant in Delaware, becoming the latest drugmaker to invest in the U.S. as tariffs targeting the industry loom. The ...

She regularly appears on CBS News 24/7 to discuss her reporting. Merck is investing $1 billion to build a U.S. plant in Delaware, in a show of its commitment to domestic manufacturing. The move ...

Merck (NYSE: MRK) recently announced its first-quarter results, exceeding Wall Street’s expectations for both earnings and revenue. The company reported revenues of $15.53 billion and adjusted ...

Earlier this month, study results showed that molnupiravir, Merck’s investigational antiviral ... The New Ultimate 1200-HP Supercar ...

About two months after receiving a sizable taxpayer-funded grant, Merck & Co. officially announced it would build its newest manufacturing facility near Elsmere. A groundbreaking ceremony was held ...

Merck KGaA is building up its portfolio and pipeline with a $3.9 billion deal to acquire SpringWorks Therapeutics, a company with two FDA-approved rare tumor drugs, both of which offer the ...

German drug company Merck KGaA said Monday it has struck a deal to buy U.S. biotech firm SpringWorks Therapeutics for around $3.9 billion, expanding its portfolio of rare disease and cancer ...